Immunotherapy Drugs Market Size 2025-2029
The immunotherapy drugs market size is forecast to increase by USD 220.8 billion, at a CAGR of 12.4% between 2024 and 2029.
The global immunotherapy drugs market is shaped by the persistent demand for more effective treatments for chronic conditions. The escalating incidence of cancer creates a significant need for innovative therapeutic approaches beyond traditional methods. This demand is being met by the ascendancy of personalized cancer vaccines, a key trend in the therapeutic vaccines space. These vaccines, which are a cornerstone of the cancer immunotherapy market, leverage a patient's unique tumor neoantigens to stimulate a targeted immune response, representing a significant move toward truly individualized oncology treatment.This advancement toward personalized medicine is creating a fertile ground for innovation and is a transformative force in the global fight against cancer. However, the substantial cost associated with these innovative treatments presents a considerable barrier to patient access. High prices create complex reimbursement landscapes for healthcare systems worldwide. This financial pressure, a key aspect of the immunosuppressants market, places a heavy burden on both patients and payers, a situation that is often compounded by the extended duration of many immunotherapy regimens.
What will be the Size of the Immunotherapy Drugs Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The ongoing evolution of the global immunotherapy drugs market is characterized by a deep exploration of the tumor microenvironment to inform the development of next-generation treatments. Research into overcoming therapeutic resistance mechanisms is leading to novel combination therapies and approaches designed to enhance clinical outcomes. These efforts are central to expanding the applicability of treatments in the broader immunology market and improving patient response rates across various indications.Advancements are particularly notable in the development of personalized cancer vaccines and the refinement of cell-based therapies. The application of logic-gated CAR T-cell therapies exemplifies the move toward greater precision and safety in the large molecule injectable drugs market. Concurrently, the development of bispecific antibodies that can engage multiple targets is opening new avenues for immune system modulation. These dynamics reflect a continuous push for more effective and targeted interventions within the cancer immunotherapy market.
How is this Immunotherapy Drugs Industry segmented?
The immunotherapy drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- End-user
- Type
- Monoclonal antibodies
- Vaccines
- Immune checkpoint inhibitors
- Others
- Therapeutic area
- Cancer
- Autoimmune and inflammatory diseases
- Infectious diseases
- Others
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
By End-user Insights
The hospitals segment is estimated to witness significant growth during the forecast period.
Hospitals are the primary end-user for the administration of complex immunotherapy drugs, particularly novel treatments requiring significant infrastructure and specialized personnel. The intensive monitoring needed for therapies and the management of potential adverse effects, such as cytokine release syndrome, solidifies the central role of the hospital setting. However, the financial burden of these treatments is substantial, encompassing not only drug acquisition costs but also facility upgrades and specialized staff training, creating significant operational pressures.
These financial and logistical challenges limit broader implementation, with reports indicating that only 16 percent of specialized centers have adequate access to certain advanced cell therapies. This pressure is a key factor driving hospitals to optimize treatment pathways and explore transitioning suitable patients to outpatient settings where feasible. Concurrently, hospitals are establishing dedicated immuno-oncology toxicity teams to manage adverse events, highlighting the need for specialized expertise to safely administer these potent therapies and incorporate new therapeutic options.
Request Free Sample
The Hospitals segment was valued at USD 103.3 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 45.6% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
North America is the dominant force in the global immunotherapy drugs market, a leadership position supported by its well-established healthcare infrastructure and substantial investments in research and development. The region's robust regulatory framework is conducive to innovation, and a high concentration of leading biopharmaceutical corporations drives research and commercialization efforts. Strong government support for cancer research and favorable reimbursement policies further facilitate patient access to high-cost treatments, stimulating market growth and reinforcing the region's prominent standing.
The North America market's significant position is also fueled by the high prevalence of chronic conditions, which creates sustained demand for advanced therapeutic options. The region is projected to contribute 45.6% of the market's incremental growth, underscoring its central role in the global landscape. Continuous advancements, such as the approval of novel treatments and more convenient drug administration methods like injectable formulations, exemplify the region's commitment to advancing the standard of care and maintaining its leadership in immunotherapy.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global immunotherapy drugs market is experiencing significant growth, driven by a focus on enhancing therapeutic efficacy in oncology. Key drivers include the rapid development of bispecific antibodies and ongoing advancements in CAR-T cell therapy. Researchers are intensively exploring the tumor microenvironment to improve strategies for targeting solid tumors with immunotherapy. Concurrently, the utility of checkpoint inhibitors in new indications continues to expand, often as part of optimizing combination immunotherapy strategies. The promising development of personalized cancer vaccines, heavily influenced by the role of MRNA technology in vaccines, is another critical frontier, with the clinical validation of neoantigen therapies being a major focus for market leaders.While the market expands, stakeholders are actively tackling significant hurdles. A primary concern is managing immune-related adverse events and overcoming therapeutic resistance mechanisms. Efforts are also focused on improving safety profiles of cell therapies through advancements like the application of logic-gated CAR T-cell therapies. Operationally, streamlining complex manufacturing processes for cell therapies is crucial, alongside the development of off-the-shelf allogeneic CAR-T therapies to increase accessibility. Market access hinges on addressing high cost of immunotherapy treatments and successfully navigating reimbursement hurdles for novel drugs. Future growth vectors include innovations in subcutaneous immunotherapy formulations and expanding applications to autoimmune diseases, representing new frontiers for these powerful treatments.
What are the key market drivers leading to the rise in the adoption of Immunotherapy Drugs Industry?
- The escalating incidence of chronic diseases and cancer worldwide serves as a foundational driver for the expansion of the global immunotherapy drugs market.
The increasing global prevalence of chronic diseases, particularly cancer, is a primary factor driving demand for advanced therapeutic options. The growing patient population requires more effective and durable treatments than what traditional therapies can offer. This sustained need for innovative solutions is amplified by demographic shifts, such as an aging population, with projections indicating that nearly one-fourth of the population in some developed nations will be over 60 years old in the coming years. Immunotherapy, with its mechanism of leveraging the body's own immune system, offers a paradigm shift in treatment, providing not only a potent modality but also the potential for long-term remission and improved quality of life, directly addressing the critical unmet needs of this expanding patient base.A continuous wave of technological and therapeutic innovation is redefining standards of care and expanding the market. Central to this is the rapid evolution of cell-based therapies and the development of bispecific antibodies. For example, advancements in personalized vaccines, when used in combination with other treatments, have shown a 44 percent reduction in the risk of recurrence or death in certain patient cohorts. Concurrently, the field of bispecific antibodies is proving highly effective with dual-targeting mechanisms. These pioneering advancements, along with progress in antibody-drug conjugates and the use of artificial intelligence in drug discovery, collectively enhance therapeutic efficacy, broaden the range of treatable diseases, and support market expansion.
What are the market trends shaping the Immunotherapy Drugs Industry?
- The ascendancy of personalized cancer vaccines represents a significant emerging trend, signaling a shift toward truly individualized oncology treatment.
The market is experiencing a paradigm shift with the accelerated development of personalized cancer vaccines. This trend involves using a patient's unique tumor neoantigens to trigger a targeted immune response, moving toward truly individualized oncology treatment. Advancements in genomic sequencing and mRNA technologies are significant enablers of this approach. This synergy between biotechnology and AI is creating fertile ground for innovation within the therapeutic vaccines space. This approach is further propelled by the integration of artificial intelligence, which enhances the precision and speed of vaccine development, potentially reducing time to market and making personalized cancer vaccines a transformative force in the cancer immunotherapy market.Chimeric antigen receptor (CAR)-T cell therapy continues to be a major trend, marked by significant expansion beyond its initial applications in hematological malignancies. The focus is increasingly shifting toward tackling the complexities of solid tumors and exploring uses in autoimmune diseases. In some healthcare systems, 79 percent of CAR-T therapies were administered in the inpatient setting, reflecting the intensity of care required. The development of off-the-shelf allogeneic car-t therapies, which use cells from healthy donors, is a significant area of research aimed at addressing manufacturing and accessibility challenges globally. Such innovations are crucial for the evolution of the large molecule injectable drugs market.
What challenges does the Immunotherapy Drugs Industry face during its growth?
- The high cost of immunotherapy treatments, coupled with significant reimbursement hurdles, presents a major challenge to market growth and patient access.
The substantial cost associated with innovative treatments is a primary challenge, creating a considerable barrier to patient access and complex reimbursement landscapes. The high price of these drugs, particularly in the case of long-term administration, places a heavy burden on both patients and payers. This financial toxicity is a global issue, with disparities in access observed between and within regions. In some areas, only 16 percent of specialized centers reported adequate access to certain advanced cell therapies, underscoring the financial and logistical challenges that healthcare systems face in providing these cutting-edge treatments to all eligible patients.The development of therapeutic resistance and the effective management of immune-related adverse events represent a significant clinical challenge. A substantial portion of patients either do not respond to initial treatment or develop resistance over time. Understanding the complex biological mechanisms of this resistance, such as the role of the gut microbiome in influencing patient outcomes, is a major focus of research. With projections suggesting that over 30% of new cancer cases can result in death, overcoming therapeutic resistance is critical. Additionally, managing toxicities, which can affect any organ system and range from mild to life-threatening, requires specialized protocols and expertise to expand the clinical benefit of immunotherapy.
Exclusive Customer Landscape
The immunotherapy drugs market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the immunotherapy drugs market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, immunotherapy drugs market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AbbVie Inc. - The offerings in this market encompass a specialized class of biopharmaceuticals designed to modulate the body's immune system. These include a diverse range of products such as monoclonal antibodies targeting specific antigens, therapeutic vaccines, and immune checkpoint inhibitors that release the brakes on the immune system. Additionally, the portfolio features advanced treatments like cell-based therapies, including those involving genetically modified T-cells, which are developed for use across multiple therapeutic areas, primarily in oncology and autoimmune disorders.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- BioNTech SE
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celldex Therapeutics Inc
- F. Hoffmann La Roche Ltd.
- Genmab AS
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Incyte Corp.
- Johnson and Johnson Services Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Immunotherapy Drugs Market
In June 2024, AstraZeneca's Imfinzi, in combination with chemotherapy, was approved in the European Union for treating adult patients with locally advanced and metastatic biliary tract cancer.In June 2024, Bristol Myers Squibb received approval from the US Food and Drug Administration for Augtyro for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.In April 2024, Moderna and Merck announced that their investigational personalized neoantigen therapy, mRNA-4157 (V940), in combination with KEYTRUDA, demonstrated a statistically significant improvement in overall survival for patients with high-risk melanoma following complete resection.In February 2024, Novartis announced it had entered into a merger agreement to acquire MorphoSys AG, a German biopharmaceutical company developing treatments for cancer, for EUR 2.7 billion.
Research Analyst Overview
The global immunotherapy drugs market continues to evolve with advancements in immune checkpoint inhibitors, specifically pd-1/pd-l1 inhibitors and ctla-4 inhibitors, which are foundational biologic agents. The application of monoclonal antibodies and antibody-drug conjugates is expanding beyond hematologic malignancies to address the complexities of solid tumor treatments. This progression in host immune system modulation is focused on overcoming therapeutic resistance mechanisms and adaptive resistance mechanisms that limit efficacy. Further developments in areas like janus kinase inhibitors and oncolytic virus therapy are also reshaping approaches to modulating the tumor microenvironment and managing pro-inflammatory cytokines, with pipeline expansion exceeding 11% in recent periods.The domain of cellular immunotherapy is being transformed by chimeric antigen receptor t-cell innovations, including cd19 car-t cell therapy and more advanced logic-gated car t-cells. Development of allogeneic car-t therapies and other off-the-shelf immunotherapies aims to standardize adoptive cell therapy. Concurrently, managing immuno-oncology toxicity, such as immune-related adverse events and cytokine release syndrome, remains a critical focus. Emerging modalities like personalized cancer vaccines, leveraging mrna technology and detailed analysis of tumor neoantigens through genomic sequencing, are becoming more prevalent. These complex treatments, including t-cell receptor therapies, necessitate a secure cryogenic chain of custody from manufacturing to administration.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Immunotherapy Drugs Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
294
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 12.4%
|
|
Market growth 2024-2029
|
USD 220.8 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
11.3%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, Russia, Spain, The Netherlands, China, Japan, India, South Korea, Singapore, Indonesia, Thailand, Brazil, Saudi Arabia, South Africa, Turkey, UAE, Australia
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Immunotherapy Drugs Market Research and Growth Report?
- CAGR of the Immunotherapy Drugs industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the immunotherapy drugs market growth of industry companies
We can help! Our analysts can customize this immunotherapy drugs market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Therapeutic Area
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Immunotherapy Drugs Market 2019 - 2023
- Historic Market Size - Data Table on Global Immunotherapy Drugs Market 2019 - 2023 ($ billion)
- 5.2 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ billion)
- 5.3 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)
- 5.4 Therapeutic Area segment analysis 2019 - 2023
- Historic Market Size - Therapeutic Area Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 Impact of AI in global immunotherapy drugs market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by End-user
- 8 Market Segmentation by End-user
- 8.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 8.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 8.3 Hospitals - Market size and forecast 2024-2029
- Chart on Hospitals - Market size and forecast 2024-2029 ($ billion)
- Data Table on Hospitals - Market size and forecast 2024-2029 ($ billion)
- Chart on Hospitals - Year-over-year growth 2024-2029 (%)
- Data Table on Hospitals - Year-over-year growth 2024-2029 (%)
- 8.4 Clinics - Market size and forecast 2024-2029
- Chart on Clinics - Market size and forecast 2024-2029 ($ billion)
- Data Table on Clinics - Market size and forecast 2024-2029 ($ billion)
- Chart on Clinics - Year-over-year growth 2024-2029 (%)
- Data Table on Clinics - Year-over-year growth 2024-2029 (%)
- 8.5 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ billion)
- Data Table on Market opportunity by End-user ($ billion)
9 Market Segmentation by Type
- 9 Market Segmentation by Type
- 9.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
- 9.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 9.3 Monoclonal antibodies - Market size and forecast 2024-2029
- Chart on Monoclonal antibodies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Monoclonal antibodies - Market size and forecast 2024-2029 ($ billion)
- Chart on Monoclonal antibodies - Year-over-year growth 2024-2029 (%)
- Data Table on Monoclonal antibodies - Year-over-year growth 2024-2029 (%)
- 9.4 Vaccines - Market size and forecast 2024-2029
- Chart on Vaccines - Market size and forecast 2024-2029 ($ billion)
- Data Table on Vaccines - Market size and forecast 2024-2029 ($ billion)
- Chart on Vaccines - Year-over-year growth 2024-2029 (%)
- Data Table on Vaccines - Year-over-year growth 2024-2029 (%)
- 9.5 Immune checkpoint inhibitors - Market size and forecast 2024-2029
- Chart on Immune checkpoint inhibitors - Market size and forecast 2024-2029 ($ billion)
- Data Table on Immune checkpoint inhibitors - Market size and forecast 2024-2029 ($ billion)
- Chart on Immune checkpoint inhibitors - Year-over-year growth 2024-2029 (%)
- Data Table on Immune checkpoint inhibitors - Year-over-year growth 2024-2029 (%)
- 9.6 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 9.7 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)
10 Market Segmentation by Therapeutic Area
- 10 Market Segmentation by Therapeutic Area
- 10.1 Market segments
- Chart on Therapeutic Area - Market share 2024-2029 (%)
- Data Table on Therapeutic Area - Market share 2024-2029 (%)
- 10.2 Comparison by Therapeutic Area
- Chart on Comparison by Therapeutic Area
- Data Table on Comparison by Therapeutic Area
- 10.3 Cancer - Market size and forecast 2024-2029
- Chart on Cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Cancer - Year-over-year growth 2024-2029 (%)
- 10.4 Autoimmune and inflammatory diseases - Market size and forecast 2024-2029
- Chart on Autoimmune and inflammatory diseases - Market size and forecast 2024-2029 ($ billion)
- Data Table on Autoimmune and inflammatory diseases - Market size and forecast 2024-2029 ($ billion)
- Chart on Autoimmune and inflammatory diseases - Year-over-year growth 2024-2029 (%)
- Data Table on Autoimmune and inflammatory diseases - Year-over-year growth 2024-2029 (%)
- 10.5 Infectious diseases - Market size and forecast 2024-2029
- Chart on Infectious diseases - Market size and forecast 2024-2029 ($ billion)
- Data Table on Infectious diseases - Market size and forecast 2024-2029 ($ billion)
- Chart on Infectious diseases - Year-over-year growth 2024-2029 (%)
- Data Table on Infectious diseases - Year-over-year growth 2024-2029 (%)
- 10.6 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 10.7 Market opportunity by Therapeutic Area
- Market opportunity by Therapeutic Area ($ billion)
- Data Table on Market opportunity by Therapeutic Area ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 12.4.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.4.7 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 12.5.6 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.5.7 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.3 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.4 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.6.5 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.6 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Escalating incidence of chronic diseases and cancer
- Pioneering technological and therapeutic innovations
- Robust investment and strategic collaborations in research and development
- 13.2 Market challenges
- High cost of treatment and reimbursement hurdles
- Mechanisms of therapeutic resistance and management of toxicities
- Complex manufacturing processes and supply chain logistics
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Ascendancy of personalized cancer vaccines
- Expansion and innovation in CAR-T cell therapy
- Rapid development and approval of bispecific antibodies
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
- 15.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 15.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.8 BioNTech SE
- BioNTech SE - Overview
- BioNTech SE - Product / Service
- BioNTech SE - Key offerings
- SWOT
- 15.9 Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Product / Service
- Boehringer Ingelheim International GmbH - Key news
- Boehringer Ingelheim International GmbH - Key offerings
- SWOT
- 15.10 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.11 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.12 Genmab AS
- Genmab AS - Overview
- Genmab AS - Product / Service
- Genmab AS - Key offerings
- SWOT
- 15.13 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Product / Service
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- SWOT
- 15.14 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.15 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
- 15.16 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.17 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 15.18 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
